Scientist at Formurex Inc
Dr. Satyanarayana Goda, currently working as a Product Development Scientist at Formurex, Inc. He has over 15 years’ experience in pre-clinical and Formulation development, specializing in development of oral and topical dosage forms. He has vast experience in characterization of new chemical entities (NCE’S) for early stage dosage form development, preparation of Nano particles, spray dried powders, solubility screening, Bio-availability enhancement, granulation and fluid bed drying, Compression using rotary tablet press, coating, stability studies, scale up, and tech transfer etc. Dr. Goda received Ph.D. in Pharmaceutical Sciences in 2011 from Texas Tech School of Pharmacy, Amarillo, TX. Before coming to US in 2006, he earned Bachelor and Masters in Pharmacy from Kakatiya University, Warangal, India. During his Ph.D, he worked on several projects, specializing in improving drug delivery to the brain by novel bio-conjugate systems [Paclitaxel-angiopep conjugate (Ang 1005) and doxorubicin-angiopep conjugate (Ang 1007)], neuropharmacokinetics and pharmacodynamics, role of transporters at the blood brain barrier (BBB) in normal and disease states, developed and validated LC-MS/MS (Varian Inc.) method for loop diuretics, anti-cancer drugs in various matrices i.e. brain, plasma, and CSF, tumors; In vitro transport assays using MDCK cell lines, efflux studies, protein binding, in-situ brain perfusion method, animal handling and their surgeries etc. During his M.S in Pharmacology, developed clinical pharmacokinetic mathematical and mechanistic models for gentamicin in Indian pediatric patients using NONMEM and also Therapeutic drug monitoring of anti-epileptic drugs i.e. carbamazepine, valproate, phenytoin, phenobarbital etc. using HPLC. Dr.Goda has presented and published in the area of drug delivery to brain, brain ischemia and brain tumors in various national and international platforms and won many accolades. He has been serving as an Editor for Global Journal of Obesity, Diabetes and Metabolic Syndrome, guest editor for Genetic evolution of Cancer, reviewer for various reputed Journals like Experts Opinion on Drug Delivery, Controlled Drug Delivery, Advanced Drug Delivery Reviews, Journal of Bioavailability and Bio equivalence, Journal of Drug Delivery Science and Technology, Journal of Pharmaceutical Research and Clinical Practice, Abstract screener for AAPS annual meetings. He is a member of American association of pharmaceutical scientists (AAPS), society for neuroscience (SFN) and International blood-brain barrier society (IBBS). Within AAPS, he is a member of Formulation Design and Development (FDD), Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPD and Clinical Pharmacology and Translational Research (CPTR) sections.
• Solubility screening and their bio-availability enhancement
• Drug delivery (Immediate, controlled release etc.)
• Pharmaceutical Drug Development (Oral and Topical)
• Pre-clinical and clinical formulations
• Pre-formulation studies
• Spray drying, Nanoparticles etc.
• Blood-Brain Barrier, Transporters
• Breast Cancer Metastasis
• CNS Pharmacokinetics